Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02502006 · ClinicalTrials.gov registry record · Phase 1

Variability in Response to Non-steroidal Anti-inflammatory Drugs

A Phase 1 study, sponsored by University of Pennsylvania.

Terminated
Registry status
Phase 1
Development phase
16
Enrollment target

NCT02502006: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.

NCT02502006 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02502006, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability.

Interventions

  • DRUG Placebo
  • DRUG Celecoxib
  • DRUG Naproxen

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2015-11
Est. Completion 2022-09
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02502006

The ClinicalTrials.gov registry entry for NCT02502006 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02502006 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02502006 about?

NCT02502006 is a clinical study titled "Variability in Response to Non-steroidal Anti-inflammatory Drugs". This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability.

What is the current status of trial NCT02502006?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-11. Estimated completion is 2022-09.

What interventions are being tested in trial NCT02502006?

The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Naproxen (DRUG).

Who is sponsoring clinical trial NCT02502006?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.